JAC Advance Access originally published online on January 6, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 297-304
© 2003 The British Society for Antimicrobial Chemotherapy
Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine
1 Department of Microbiology, 2 Section of Infectious Diseases, Department of Medicine, Hope Hospital, Eccles Old Road, Salford M6 8HD; 3 School of Medicine, University of Manchester, Manchester M13 9PL, UK
Received 12 April 2001; returned 20 June 2001; revised 4 February 2002; accepted 5 November 2002
Optimal methods for susceptibility testing of Candida spp. with flucytosine have not been determined. Breakpoints were recommended in 1984, but never validated. In this study, we compared the 1984 recommended macrodilution broth method (using an 80% endpoint) with a modification of the more recent NCCLS-recommended microdilution broth method with three endpoints—spectrophotometric 50% and 80% and a no growth endpoint determined by eye. NCCLS and British Society for Medical Mycology (BSMM) breakpoints were also compared. One hundred and fifty isolates comprised of Candida albicans, Candida tropicalis, Candida krusei, Candida glabrata, Candida parapsilosis and Candida lusitaniae were tested. Reproducibility was excellent. For C. albicans (n = 65), the correlation between tests was excellent (>75%), with few major discrepancies (<5%). For C. tropicalis (n = 27), correlation was good (59%), but there were a small number of major discrepancies (up to 11%, depending on breakpoint used). Results by the broth macrodilution method were generally higher than both microdilution methods for C. glabrata (n = 16; correlation of 18.8%), but only one major discrepancy was seen. Ten of the 11 C. parapsilosis isolates tested were susceptible by all methods, regardless of breakpoint chosen, with a correlation of 18.2%, but no major discrepancies were seen. A correlation between all methods (50%) was seen with C. lusitaniae (n = 10), with many isolates resistant or intermediate. In contrast, correlation between methods for C. krusei was poor (<5%); NCCLS microtitre modification produced results that were classified as intermediate or resistant, regardless of the breakpoint used. The methodology for susceptibility testing C. albicans is robust. Additional work to optimize susceptibility testing with flucytosine is necessary for non-albicans Candida species, especially C. krusei.
* Correspondence address. Research and Teaching Block, Wythenshawe Hospital, Southmoor Road, Manchester M29 9LT, UK. Tel: +44-161-291-5811; Fax: +44-161-291-5806; E-mail: ddenning{at}man.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Lalitha, B. L. Shapiro, M. Srinivasan, N. V. Prajna, N. R. Acharya, A. W. Fothergill, J. Ruiz, J. D. Chidambaram, K. J. Maxey, K. C. Hong, et al. Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolated From Keratitis Arch Ophthalmol, June 1, 2007; 125(6): 789 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Favel, A. Michel-Nguyen, A. Datry, S. Challier, F. Leclerc, C. Chastin, K. Fallague, and P. Regli Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents J. Antimicrob. Chemother., March 1, 2004; 53(3): 526 - 529. [Abstract] [Full Text] [PDF]
|
|